



Effective Date11/15/2024
Coverage Policy Number IP0294

Pegvaliase-pqpz

Table of Contents

Overview1
Medical Necessity Criteria1
Reauthorization Criteria2
Authorization Duration2
Conditions Not Covered.....2
Background.....2
References3
Revision Details4

Related Coverage Resources

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This policy supports medical necessity review for pegvaliase-pqpz subcutaneous injection (**Palynziq**[®]).

Medical Necessity Criteria

Pegvaliase-pqpz (Palynziq) is considered medically necessary when the following are met:

Phenylketonuria (PKU). Individual meets **ALL** of the following criteria:

- A. Age 18 years or older
- B. Documented diagnosis of phenylketonuria (PKU) confirmed by documentation of **ONE** of the following:
 - i. Plasma phenylalanine concentration persistently above 120 µmol/L (2 mg/dL) and altered ratio of phenylalanine to tyrosine in the untreated state with normal BH4 cofactor metabolism
 - ii. Molecular genetic test demonstrating biallelic pathogenic or likely pathogenic variants in the *PAH* gene

- C. Documentation of uncontrolled blood phenylalanine concentrations of greater than 600 micromol/L on existing management (for example, phenylalanine restricted diet, sapropterin [Kuvan])
 - D. Medication is prescribed by, or in consultation with, a metabolic disease specialist, or specialist who focuses in the treatment of metabolic diseases
-

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

Reauthorization Criteria

Continuation of Pegvaliase-pqpz (Palynziq) is considered medically necessary for the treatment of Phenylketonuria (PKU) when **BOTH** of the following are met (1 and 2):

1. The above medical necessity criteria have been met prior to the start of Palynziq therapy
2. Patient meets **ONE** of the following (a or b):
 - a. Patient meets **BOTH** of the following (i and ii):
 - i. Is continuing to titrate Palynziq to an effective maintenance dose, per the prescriber
 - ii. If the patient is receiving a dose of Palynziq 60 mg once daily, the treatment duration at this dose has not exceeded 16 weeks
 - b. Patient meets **BOTH** of the following (i and ii):
 - i. Patient meets **ONE** of the following (A or B):
 - A. Blood phenylalanine levels are being maintained within an acceptable range (120-600 µmol/L)
 - B. Individual has achieved a greater than or equal to 20% reduction in blood phenylalanine concentration from pre-treatment baseline
 - ii. Patient is not receiving concomitant therapy with sapropterin (Kuvan)

Authorization Duration

Initial approval duration: up to 12 months.

Reauthorization approval duration: up to 12 months.

Conditions Not Covered

Any other use is considered experimental, investigational or unproven.

Background

OVERVIEW

Palynziq, a phenylalanine-metabolizing enzyme, is indicated to reduce blood phenylalanine concentrations in adult patients with **phenylketonuria (PKU)** who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.¹

Treatment with Palynziq should be managed by a healthcare provider experienced in the management of PKU. Baseline blood phenylalanine concentrations should be obtained before initiating treatment. Because of the risk of anaphylaxis, Palynziq is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program.

Dose Titration

The recommended initial induction dosage for Palynziq is 2.5 mg subcutaneously (SC) for 4 weeks.¹ This dose is then titrated over a period of at least 5 weeks to a maintenance dose of 20 mg SC once daily (QD). The maintenance dose should be individualized to achieve blood phenylalanine control (blood phenylalanine concentration \leq 600 micromol/L). Maintain the Palynziq 20 mg QD dose for at least 24 weeks. Consider increasing the Palynziq dose to 40 mg QD in a patient who has been on 20 mg QD for at least 24 weeks without achieving blood phenylalanine control. Consider increasing the Palynziq dose to a maximum of 60 mg QD in a patient who has been on 40 mg QD for at least 16 weeks without achieving blood phenylalanine control. Discontinue Palynziq in a patient who has not achieved an adequate response after continuous treatment with the maximum dose of 60 mg QD for 16 weeks. A dose titration schedule is outlined in Table 1. Therapeutic response may not be achieved until the patient is titrated to an effective maintenance dose.

Table 1. Palynziq Dose Titration.¹

Treatment	Palynziq Dose	Duration*
Induction	2.5 mg once weekly	4 weeks
Titration	2.5 mg twice weekly	1 week
	10 mg once weekly	1 week
	10 mg twice weekly	1 week
	10 mg four times weekly	1 week
	10 mg QD	1 week
Maintenance	20 mg QD	24 weeks
	40 mg QD	16 weeks
Maximum	60 mg QD	16 weeks
Total	--	65 weeks

* Additional time may be required prior to each dosage escalation based on patient tolerability; QD – Once daily.

It was unclear from the Palynziq clinical trials if all patients had tried and were non-responders to sapropterin.

Guidelines

Recommendations regarding use of Palynziq are not made in guidelines from the American College of Medical Genetics and Genomics (ACMG) [2014] or European guidelines (2017).^{2,3} However, a consensus statement regarding use of Palynziq in adults with PKU was published in 2019.⁴ Palynziq should be considered for all adults with PKU who have the ability to give informed consent and adhere to treatment. It is noted that some patients may show a response early on, whereas other may take 1 year or more from initiation of treatment before a reduction in blood phenylalanine concentration is observed. The definition of a “clinically meaningful” efficacy benefit should be determined by the treating clinician based on individual patient goals. Primarily, the efficacy benefit should be determined by a significant reduction in blood phenylalanine concentration from baseline.

Although ACMG and European guidelines do not offer recommendations specific to Palynziq, they do provide general principles for PKU management. ACMG guidelines suggest a target blood phenylalanine level of 120 to 360 micromol/L for all patients.² However, European guidelines state that patients \geq 12 years of age with blood phenylalanine concentration $<$ 600 micromol/L do not require treatment, and the target range for patients \geq 12 years of age receiving treatment is 120 to 600 micromol/L.³

References

1. Palynziq™ subcutaneous injection [prescribing information]. Novato, CA: BioMarin; November 2020.
2. Vockley J, Andersson HC, Antshel KM, et al; American College of Medical Genetics and Genomics Therapeutics Committee. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. *Genet Med*. 2014 Feb;16(2):188-200.
3. van Wegberg AMJ, MacDonald A, Ahring A, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. *Orphanet J Rare Dis*. 2017;12:162.
4. Longo N, Dimmock D, Levy H, et al. Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. *Genet Med*. 2019 Aug;21(8):1851-1867.

Revision Details

Type of Revision	Summary of Changes	Date
Selected Revision	<p>Phenylketonuria (PKU): Removed the requirement for Palynziq to be prescribed in conjunction with a phenylalanine restricted diet. Removed the no concomitant use with sapropterin (Kuvan), once stabilized on Palynziq. This requirement has been moved to the reauthorization criteria.</p> <p>Reauthorization Criteria: Added a statement limiting the treatment duration, at a dose of 60 mg, to 16 weeks. Added a statement prohibiting concomitant therapy with sapropterin (Kuvan).</p>	11/15/2024

The policy effective date is in force until updated or retired.

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.